NanoViricides wins DRC ethics approval for Phase II trial of NV-387 oral gummies for Ebola

• NanoViricides received DRC National Ethics Committee clearance for a Phase II trial of NV-387 oral gummies to treat Bundibugyo Ebola.
• The company is preparing to submit a clinical trial application to ACOREP, the DRC regulator, to start the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607130927ACCESSWRNAPR_____1190201) on July 13, 2026, and is solely responsible for the information contained therein.